Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.

NCT01415518 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01415518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01415518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 1, 2011
Completion date
December 1, 2012
Enrollment
581 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)